Interim 发表于 2025-3-25 03:48:04

http://reply.papertrans.cn/1/57/5680/5680-21.png

表两个 发表于 2025-3-25 07:41:25

Submitted on: 10 January 2020.
Revised on: 15 April 2020.
Accepted on: 03 June 2020.

___________________CLINICAL NEUROPHARMACOLOGY---LIPPINCOTT WILLIAMS & WILKINS

Ambulatory 发表于 2025-3-25 13:41:31

Submitted on: 26 June 2024.
Revised on: 21 September 2024.
Accepted on: 24 October 2024.

___________________CLINICAL NEUROPHARMACOLOGY---LIPPINCOTT WILLIAMS & WILKINS

Asseverate 发表于 2025-3-25 16:13:17

http://reply.papertrans.cn/1/57/5680/5680-24.png

禁止,切断 发表于 2025-3-25 21:42:42

http://reply.papertrans.cn/1/57/5680/5680-25.png

碎石 发表于 2025-3-26 01:47:51

http://reply.papertrans.cn/1/57/5680/5680-26.png

松鸡 发表于 2025-3-26 04:29:16

http://reply.papertrans.cn/1/57/5680/5680-27.png

胎儿 发表于 2025-3-26 11:47:11

http://reply.papertrans.cn/1/57/5680/5680-28.png

moratorium 发表于 2025-3-26 13:56:40

Submitted on: 28 November 2018.
Revised on: 26 December 2018.
Accepted on: 15 January 2019.

___________________CLINICAL NEUROPHARMACOLOGY---LIPPINCOTT WILLIAMS & WILKINS

缩影 发表于 2025-3-26 17:12:02

Submitted on: 24 November 2024.
Revised on: 03 March 2025.
Accepted on: 11 April 2025.

___________________CLINICAL NEUROPHARMACOLOGY---LIPPINCOTT WILLIAMS & WILKINS
页: 1 2 [3] 4
查看完整版本: SCIE期刊CLINICAL NEUROPHARMACOLOGY 2024/2025影响因子:0.816 (CLIN NEUROPHARMACOL) (0362-5664). (PHARMACOLOGY & PHARMACY)(药理学与药